Group items tagged

Researchers at at an Australian university have developed a new form of antibiotic that can be swiftly re-engineered to avoid resistance to dangerous superbugs. The antibiotic, which was developed by PhD candidate Priscila Cardoso and major supervisor Dr Celine Valery from RMIT's School of Health and Biosciences, has a basic architecture that allows it to be generated quickly and cheaply in a lab. The antibiotic, Priscilicidin, has tiny amino acid building blocks that allow it to be tailored to combat various types of antimicrobial resistance. With the World Health Organization calling antimicrobial resistance "one of the top ten global public health threats facing humanity", developing new antibiotics has become more urgent than ever. Professor Charlotte Conn, one of Cardoso's PhD supervisors, said given that urgency, Priscilicidin was an exciting breakthrough for public health. Priscilicidin is a type of antimicrobial peptide. These peptides are produced by all living organisms as the first defence against bacteria and viruses.

Experts suggest that the new Respiratory Syncytial Virus (RSV) vaccination programme, being rolled out in hospitals and community pharmacies, will not only reduce the burden of RSV infections in England but also contribute to a reduction in antibiotic prescriptions. While antibiotics are ineffective against viruses, they are sometimes prescribed in primary care because it is difficult to distinguish between bacterial and viral infections. A study conducted by the UK Health Security Agency (UKHSA), Imperial College London, and Oxford Population Health revealed that RSV infections result in 640,000 antibiotic prescriptions a year. The study suggests that interventions to reduce RSV infections, including the new vaccine programme, could lower antibiotic use and, in turn, reduce antibiotic resistance. RSV typically causes mild respiratory symptoms in most individuals, but it can lead to serious illness and hospitalisation in vulnerable groups, such as infants and older adults.

The government has launched the Global AMR Innovation Fund (GAMRIF) on Monday (22 May), under which it has announce up to £39 million fund for antimicrobial resistance (AMR) research. Of this new funding package, up to £24 million over four years has been awarded to bolster the UK's partnership with CARB-X - a global AMR research initiative - to support the continued early development of invaluable new antibiotics, vaccines, rapid diagnostics and other products to combat life threatening drug-resistant infections and prevent death and disease across the world. In addition to the CARB-X grant, GAMRIF is investing £5 million over two years into the Global Antibiotic R&D Partnership (GARDP) to develop - and ensure global access to - new antibiotic treatments against major global health priorities. The announcement comes as Health Minister Will Quince attends the World Health Assembly (WHA) in Geneva, Switzerland, and Development Minister Andrew Mitchell participates in an event on health leadership and climate change alongside the WHA. They will announce the launch of the UK government's Global Health Framework for 2023-2025, as part of Minister Quince's address at the WHA. Health Minister Will Quince said: Antimicrobial resistance is a major threat to global health and has led to millions of tragic deaths per year, but the Global AMR Innovation Fund is supporting cutting-edge research and developing vital new treatments to prevent death and disease across the world.

The UK government on Thursday (8 May) launched a new plan to tackle antimicrobial resistance (AMR), a global issue that makes infections difficult or impossible to treat. This is the second phase of a series of 5-year national action plans, aimed at supporting the government's 20-year vision to contain and control AMR by 2040. With the launch of this new national action plan, the UK commits to reducing its use of antimicrobials - such as antibiotics, antifungals and antivirals - in humans and animals. Additionally, it aims to strengthen surveillance of drug-resistant infections before they emerge and incentivise industry to develop the next generation of treatments. There are also plans to expand initiatives such as the world-first 'subscription model' for antimicrobials, launched in 2019 as a pilot.

In a collaborative effort to combat the escalating threat of antimicrobial resistance (AMR), UWE Bristol and Bedminster Pharmacy have secured grant funding from the UKRI Regional Innovation Fund (RIF) for a groundbreaking 4-month project. This initiative aims to revolutionise antimicrobial stewardship (AMS) practices at the community pharmacy level, addressing the pressing need for evidence-based approaches in tackling AMR. With antibiotic misuse contributing significantly to the rise of AMR, the project underscores the vital role of community pharmacies in promoting responsible antibiotic use. Mr Ade Williams, Superintendent Pharmacist at Bedminster Pharmacy, emphasised the significance of this endeavour, stating: